

ASX Announcement 22/10/2020

Update on AngelMed Guardian implants in Singapore

Key Highlights:

- First female patient in Singapore receives an AngelMed Guardian
- 5th patient to successfully receive AngelMed Guardian Implant in Singapore

Hydrix Limited (ASX: HYD, 'Hydrix' or the 'Company') is pleased to announce that the first female patient in Singapore has received an AngelMed Guardian implant.

The procedure was performed under the supervision of Consultant Cardiologist Dr Leslie Lam. The patient has now been discharged from hospital, is in good health, and is looking forward to resuming an active lifestyle.

Paul Kelly, Hydrix Medical General Manager, said "with each procedure, awareness of the AngelMed Guardian technology grows. We look forward to more procedures being announced in the near future".

Hydrix Medical continues to explore opportunities with key stakeholders in Australia for implants under TGA's Special Access Scheme. Subject to reaching commercial, medical, and regulatory arrangements, and to COVID-19 disruptions, there is potential for implants in Australia in the December 2020 quarter.

An estimated 500,000 people annually suffer from an acute coronary syndrome event in the top four Asia Pacific countries that Hydrix Medical is initially targeting. For context, a 1% market share could translate into over \$35 million in annual AngelMed Guardian revenues for Hydrix.

This is now the 5th patient to receive an AngelMed Guardian implant in Singapore, with all patients recovered and doing well.

-ENDS-

This announcement is authorised for release by the Board of Directors of Hydrix Limited.

Contact Details: For more information, please contact:

Company Enquiries:
Paul Kelly
Hydrix Medical - General Manager
info@hydrix.com
+61 3 9550 8100

Media Enquiries:
Rod North
Managing Director, Bourse Communications
rod@boursecommunications.com.au
+61 3 9510 8309

About Hydrix Limited

Hydrix Limited (ASX: HYD) is a powerful product innovation company. Hydrix purpose is to enhance the health, safety, and wellbeing of one Billion lives. The company leverages its powerful product innovation capability across multiple growth platforms: **Hydrix Services** design and engineer client products which transform industries; **Hydrix Ventures** generate equity returns through investing in high potential companies; and **Hydrix Medical** bring innovative medical technologies to market.